BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 28535946)

  • 1. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.
    Chen A; Smith KP; Whitfield BA; Zucchi PC; Lasco TM; Bias TE; Kirby JE; Hirsch EB
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):365-367. PubMed ID: 28535946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011.
    Lee CM; Liao CH; Lee WS; Liu YC; Mu JJ; Lee MC; Hsueh PR
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5016-22. PubMed ID: 22802253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
    Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Huang D; Yu B; Diep JK; Sharma R; Dudley M; Monteiro J; Kaye KS; Pogue JM; Abboud CS; Rao GG
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae.
    He F; Fu Y; Chen Q; Ruan Z; Hua X; Zhou H; Yu Y
    PLoS One; 2015; 10(3):e0119064. PubMed ID: 25734903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of carbapenem-resistant Enterobacteriaceae isolates from Korea.
    Kim SY; Shin J; Shin SY; Ko KS
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):486-90. PubMed ID: 23688521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of extended-spectrum β-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance.
    Koren J; Hubenakova Z; Drahovska H; Ozaee E; Markuskova B; Lichvarikova A
    Bratisl Lek Listy; 2019; 120(12):935-940. PubMed ID: 31855054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d'Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789).
    Del Franco M; Paone L; Novati R; Giacomazzi CG; Bagattini M; Galotto C; Montanera PG; Triassi M; Zarrilli R
    BMC Microbiol; 2015 Nov; 15(1):260. PubMed ID: 26552763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
    Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea.
    Jeong SH; Kim HS; Kim JS; Shin DH; Kim HS; Park MJ; Shin S; Hong JS; Lee SS; Song W
    Ann Lab Med; 2016 Nov; 36(6):529-35. PubMed ID: 27578505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
    Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.